AEterna Zentaris Inc., a global biopharmaceutical companyfocused on oncology and endocrine therapy, today announced the termination ofits agreement with sanofi-aventis U.S. dated March 5, 2009 for thedevelopment, commercialization and licensing of cetrorelix in benign prostatichyperplasia (BPH) for the U.S. market, following the Company's announcementlast week of the results for its European Phase 3 study for cetrorelix in BPH.Termination of the agreement will be effective January 9, 2010. Cetrorelix, a luteinizing hormone-releasing hormone (LHRH) antagonist, hadbeen the object of a Phase 3 program in BPH, a non-cancerous enlargement ofthe prostate which, as announced by the Company last week, did not meet itsprimary endpoint. Juergen Engel, Ph.D., AEterna Zentaris President and CEO stated, "Thetermination of our agreement with sanofi-aventis U.S. was expected in light oflast week's announcement. Our clinical development efforts will now be focusedon the following late-stage compounds: in oncology, Keryx, our partner andlicensee in North America, has just initiated a Phase 3 trial in multiplemyeloma with perifosine, our oral PI3K/Akt inhibitor compound. We are alsocurrently evaluating further development plans for AEZS-108, our targeteddoxorubicin conjugate, after recent positive Phase 2 results in ovarian andendometrial cancer. In endocrinology, we are in the process of reactivating aPhase 3 trial with our oral ghrelin agonist, AEZS-130, as a diagnostic testfor adult growth hormone deficiency."